Suven Life Science’s board has approved the enhancement of investment limits in wholly owned subsidiary (WOS) in USA Suven Neurosciences, Inc. from $25 million upto $50 million to undertake clinical trials on the molecules in the pipeline. The Board of directors of the company at its meeting held on April 15, 2019 has approved for the same.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.
